A paper published online today in the Archives of Neurology suggests that a non-invasive imaging procedure detects buildup of amyloid-β—the protein that forms sticky plaques in the brains of Alzheimer’s patients—in patterns consistent with those found in brain biopsy specimens. As reported earlier this year at the Human Amyloid Imaging meeting (see ARF related conference story) and at the International Conference on Alzheimer’s Disease in Chicago, Juha Rinne of the University of Turku, Finland, and colleagues performed PET scans using the widely used amyloid tracer Pittsburgh Compound B (PIB). Previous work had shown a correlation between PIB-PET images and amyloid deposition revealed in the same individuals at autopsy (see ARF related news story and ARF news story). However, the new study is the first to compare PIB-PET scans with Aβ accumulation in brain specimens from living people—in this case, 10 patients who had frontal cortical biopsies done as a routine procedure during monitoring for normal pressure hydrocephalus (NPH), a brain condition with concomitant AD pathology in some cases.

First author Ville Leinonen and colleagues evaluated patients for cognitive impairment (using CDR, MMSE, and CERAD measures) just prior to PIB-PET imaging, which was done two to 36 months following biopsy. As a group, the six people with Aβ deposits in the biopsy (three with tau pathology as well) had significantly higher PIB uptake in the frontal, parietal, and lateral temporal cortices and in the striatum, compared with those lacking frontal Aβ deposits. All patients with normal biopsy results also came up PIB-negative. However, one case that was clearly Aβ-positive in the biopsy turned out PIB-negative by PET, suggesting that there might be forms of Aβ that escape detection by PIB. The authors also noted that follow-up work is needed to determine the clinical significance of the Aβ detected by biopsy and PIB-PET imaging, as none of the six patients with AD-like features in this study had severe dementia.—Esther Landhuis.

Reference:
Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Nagren K, Tapiola T, Pirttila T, Rinne J, Jaaskelainen JE, Soininen H, Rinne JO. Assessment of Beta-Amyloid in a Frontal Cortical Brain Biopsy Specimen and by Positron Emission Tomography With Carbon 11-Labeled Pittsburgh Compound B. Arch Neurol. 2008;65(10). Abstract

Comments

Make a Comment

To make a comment you must login or register.

Comments on this content

No Available Comments

Comments on Primary Papers for this Article

No Available Comments on Primary Papers for this Article

References

News Citations

  1. HAI Chicago: Can PIB Predict Cognitive Decline?
  2. Amyloid Imaging: Laying PIB Concerns to Rest
  3. It Is Official: Autopsy Verifies Human PIB-Amyloid Connection

Paper Citations

  1. . Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol. 2008 Oct;65(10):1304-9. PubMed.

External Citations

  1. International Conference on Alzheimer’s Disease

Further Reading

Papers

  1. . Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol. 2008 Oct;65(10):1304-9. PubMed.

News

  1. Amyloid Imaging: Laying PIB Concerns to Rest
  2. It Is Official: Autopsy Verifies Human PIB-Amyloid Connection

Primary Papers

  1. . Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol. 2008 Oct;65(10):1304-9. PubMed.